Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Vaccine ; 29(18): 3431-7, 2011 Apr 18.
Article in English | MEDLINE | ID: mdl-21396408

ABSTRACT

BACKGROUND: A multinational clinical trial compared the safety and efficacy of intranasal trivalent live attenuated influenza vaccine (LAIV) with intramuscular trivalent inactivated vaccine (TIV) in very young children prior to the 2004-5 influenza season [1]. Wheezing was noted more often in recipients of LAIV and laboratory-confirmed influenza infection was noted more often in recipients of TIV. We sought to determine whether epidemiologic or genetic factors were associated with these outcomes. METHODS: Atopy surveys and DNA collections were performed in trial participants at two United States sites, Nashville, TN and Boston, MA. DNA samples were genotyped on Illumina Infinium 610 or 660-Quad. Standard allelic tests of association were performed. RESULTS: At the Nashville and Boston sites, a total of 99 children completed the trial, 6 (1 TIV, 5 LAIV) developed medically attended wheezing within 42 days following vaccination, and 8 (5 TIV, 3 LAIV) developed laboratory-confirmed influenza during the season. Eighty-one surveys and 70 DNA samples were collected. Family history of asthma (p=0.001) was associated with wheezing after vaccination. Of 468,458 single nucleotide polymorphisms tested in the genome-wide association study (GWAS), none achieved genome-wide significance for either wheezing after vaccination or laboratory-confirmed influenza infection. CONCLUSIONS: Family history of asthma appears to be a risk factor for wheezing after influenza vaccination. Given the limitations of the sample size, our pilot study demonstrated the feasibility of performing a GWAS but was not able to determine genetic polymorphisms associated with wheezing after influenza immunization.


Subject(s)
Influenza Vaccines/adverse effects , Respiratory Sounds/genetics , Asthma/complications , Child, Preschool , Chromosomes, Human, Pair 7/genetics , Clinical Trials as Topic , Female , Genome-Wide Association Study , Genotype , Humans , Infant , Influenza Vaccines/immunology , Influenza, Human/epidemiology , Influenza, Human/immunology , Influenza, Human/prevention & control , Male , Pilot Projects , Polymorphism, Single Nucleotide , Risk Factors
2.
Stroke ; 37(1): 151-5, 2006 Jan.
Article in English | MEDLINE | ID: mdl-16306465

ABSTRACT

BACKGROUND AND PURPOSE: Anticoagulation-related intracerebral hemorrhage (ICH) is often fatal, and rapid reversal of anticoagulation is the most appealing strategy currently available for treatment. We sought to determine whether particular emergency department (ED) interventions are effective in reversing coagulopathy and improving outcome. METHODS: Consecutive patients with warfarin-related ICH presenting to an urban tertiary care hospital from 1998 to 2004 were prospectively captured in a database. ED records were retrospectively reviewed for dose and timing of fresh-frozen plasma (FFP) and vitamin K, as well as serial coagulation measures. After excluding patients with incomplete ED records, do-not-resuscitate orders established in the ED, initial international normalized ratio (INR) < or =1.4, and for whom no repeat INR was performed, 69 patients were available for analysis. The primary outcome was a documented INR < or =1.4 within 24 hours of ED presentation. RESULTS: Patients whose INR was successfully reversed within 24 hours had a shorter median time from diagnosis to first dose of FFP (90 minutes versus 210 minutes; P=0.02). In multivariable analysis, shorter time to vitamin K, as well as FFP, predicted INR correction. Every 30 minutes of delay in the first dose of FFP was associated with a 20% decreased odds of INR reversal within 24 hours (odds ratio, 0.8; 95% CI, 0.63 to 0.99). Dosing of FFP and vitamin K had no effect. No ED intervention was associated with improved clinical outcome. CONCLUSIONS: Time to treatment is the most important determinant of 24-hour anticoagulation reversal. Although additional study is required to determine the clinical benefit of rapid reversal of anticoagulation, minimizing delays in FFP administration is a prudent first step in emergency management of warfarin-related ICH.


Subject(s)
Blood Transfusion/methods , Cerebral Hemorrhage/chemically induced , Cerebral Hemorrhage/therapy , Warfarin/adverse effects , Aged , Anticoagulants/therapeutic use , Emergency Medicine/methods , Female , Hospitals , Humans , International Normalized Ratio , Male , Middle Aged , Multivariate Analysis , Odds Ratio , Plasma/metabolism , Prospective Studies , Retrospective Studies , Time Factors , Treatment Outcome , Vitamin K/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...